Hydrochloric Acid

Hydrochloric Acid

SCHEMBL68432

CC(=O)N(C)C.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3734618 1.00
Hydrochloric Acid SCHEMBL7090823 1.00
Hydrochloric Acid SCHEMBL7972631 0.96
Hydrochloric Acid SCHEMBL7078366 0.96
Hydrochloric Acid SCHEMBL8624661 0.96
Methane SCHEMBL28805420 0.96
SCHEMBL30581185 0.95
SCHEMBL30581182 0.95
SCHEMBL1190178 0.95
SCHEMBL1925147 0.95 ALDH1A1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078142-A1 FULLY-CONTINUOUS SYNTHESIS METHOD OF CYPROTERONE ACETATE UNIV FUDAN (CN) 2026-03-19 US claimed
US-10577535-B2 Substantially solid acidizing composition for treatment of subterranean formations HALLIBURTON ENERGY SERVICES, INC. (US) 2020-03-03 US claimed
CN-104507933-B Amido quinazoline and Pyridopyrimidine derivatives 霍夫曼-拉罗奇有限公司 2017-10-31 CN claimed
CN-106562914-A Hair conditioner 林振慧 2017-04-19 CN claimed
US-20160272879-A1 SUBSTANTIALLY SOLID ACIDIZING COMPOSITION FOR TREATMENT OF SUBTERRANEAN FORMATIONS HALLIBURTON ENERGY SERVICES, INC. 2016-09-22 US claimed
WO-2015126397-A1 SUBSTANTIALLY SOLID ACIDIZING COMPOSITION FOR TREATMENT OF SUBTERRANEAN FORMATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2015-08-27 WO claimed
CN-101370799-B Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors HOFFMANN LA ROCHE 2012-09-05 CN claimed
CN-1953965-B Novel cis-imidazolines HOFFMANN LA ROCHE 2012-07-04 CN claimed
CN-101370799-A Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors HOFFMANN LA ROCHE (CH) 2009-02-18 CN claimed
CN-101155784-A Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments HOFFMANN LA ROCHE (CH) 2008-04-02 CN claimed
US-7253320-B2 Process for preparing polymorphic form II of sertraline hydrochloride SANDOZ AG (CH) 2007-08-07 US claimed
WO-2007071421-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF SERTRALINE SANDOZ AG (CH) 2007-06-28 WO claimed
CN-1953965-A Novel cis-imidazolines HOFFMANN LA ROCHE (CH) 2007-04-25 CN claimed
US-20060229472-A1 Process for preparing polymorphic form II of sertraline hydrochloride SANDOZ AG (CH) 2006-10-12 US claimed
EP-1501858-A2 FURTHER SYNTHESES OF CYPROTERONE ACETATE BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 2005-02-02 EP claimed
WO-2003092578-A2 FURTHER SYNTHESES OF CYPROTERONE ACETATE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2003-11-13 WO claimed
US-20260078142-A1 FULLY-CONTINUOUS SYNTHESIS METHOD OF CYPROTERONE ACETATE UNIV FUDAN (CN) 2026-03-19 US disclosed
US-20250257031-A1 PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2025-08-14 US disclosed
US-4026922-A PROGESTATIONAL AGENTS ALIG L 1977-05-31 US disclosed
US-3991037-A Process for preparing filaments, fibers and sheets of aromatic polyamides HOECHST AKTIENGESELLSCHAFT (DT) 1976-11-09 US disclosed